Capital Fund Management S.A. decreased its position in shares of Opko Health Inc. (NYSE:OPK) by 12.6% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 20,693 shares of the company’s stock after selling 2,972 shares during the period. Capital Fund Management S.A.’s holdings in Opko Health were worth $193,000 at the end of the most recent reporting period.
Other large investors have also recently bought and sold shares of the company. Aperio Group LLC increased its stake in Opko Health by 67.1% in the first quarter. Aperio Group LLC now owns 63,042 shares of the company’s stock worth $655,000 after buying an additional 25,312 shares during the period. Virginia Retirement System purchased a new stake in Opko Health during the first quarter worth about $510,000. Teachers Advisors Inc. increased its stake in Opko Health by 3.6% in the first quarter. Teachers Advisors Inc. now owns 325,172 shares of the company’s stock worth $3,379,000 after buying an additional 11,403 shares during the period. BlackRock Inc. increased its stake in Opko Health by 239.6% in the first quarter. BlackRock Inc. now owns 36,005 shares of the company’s stock worth $375,000 after buying an additional 25,403 shares during the period. Finally, BlackRock Group LTD increased its stake in Opko Health by 19.1% in the first quarter. BlackRock Group LTD now owns 251,817 shares of the company’s stock worth $2,616,000 after buying an additional 40,321 shares during the period.
Shares of Opko Health Inc. (NYSE:OPK) traded down 1.48% during mid-day trading on Monday, reaching $9.31. The company’s stock had a trading volume of 3,376,076 shares. Opko Health Inc. has a 12 month low of $7.12 and a 12 month high of $11.85. The company has a 50 day moving average price of $10.09 and a 200 day moving average price of $10.05. The stock has a market capitalization of $5.12 billion and a P/E ratio of 38.95.
Opko Health (NYSE:OPK) last issued its quarterly earnings results on Monday, August 8th. The company reported $0.02 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.03) by $0.05. The business earned $357.10 million during the quarter, compared to analyst estimates of $324.11 million. The company’s revenue for the quarter was up 742.2% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.09) earnings per share. On average, equities research analysts anticipate that Opko Health Inc. will post ($0.05) earnings per share for the current fiscal year.
Several equities research analysts have recently weighed in on OPK shares. Zacks Investment Research downgraded Opko Health from a “hold” rating to a “sell” rating in a research report on Friday, July 1st. Jefferies Group reaffirmed a “hold” rating on shares of Opko Health in a research report on Wednesday, August 17th. Standpoint Research upped their target price on Opko Health from $16.00 to $18.00 and gave the stock a “buy” rating in a research report on Tuesday, June 21st. Oppenheimer Holdings Inc. reaffirmed a “hold” rating on shares of Opko Health in a research report on Monday, October 10th. Finally, JPMorgan Chase & Co. set a $14.00 target price on Opko Health and gave the stock a “buy” rating in a research report on Tuesday, August 9th. Five investment analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Buy” and an average price target of $13.20.
In other Opko Health news, CEO Phillip Md Et Al Frost purchased 10,000 shares of the stock in a transaction dated Tuesday, August 2nd. The shares were bought at an average cost of $9.88 per share, with a total value of $98,800.00. Following the completion of the transaction, the chief executive officer now owns 3,068,951 shares in the company, valued at approximately $30,321,235.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Opko Health Company Profile
OPKO Health, Inc (OPKO) is a healthcare company. The Company operates through two segments: diagnostics and pharmaceutical. The pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, and its pharmaceutical research and development operations. The diagnostics segment primarily consists of its clinical laboratory operations.